EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study

Sailish Honap, Maria José Temido, Eathar Shakweh, Fakhirah Badrulhisham, Natalie Shields, Sonia Mehta, Jodie McBride, Mathieu Uzzan, Milan Lukáš, Mathurin Fumery, Akira Nogami, Taku Kobayashi und 28 weitere

Clinical Gastroenterology and Hepatology · 2026-02 · 24 (2) · 484-492.e7

DOI: 10.1016/j.cgh.2025.04.031 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-02. Verfasst von Sailish Honap und 39 weiteren Autor:innen. Beteiligte Einrichtung: School of Immunology and Microbial Sciences, King's College, London, United Kingdom; Department of Gastroenterology, Nancy University Hospital, Vandœ…. Hauptthemen laut MEDLINE: Acne Vulgaris, Inflammatory Bowel Diseases, Janus Kinase Inhibitors. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: JAK inhibitor-associated acne is a common but poorly understood adverse event. This study aimed to investigate the epidemiology, clinical characteristics, and treatment outcomes of this condition in patients with inflammatory bowel disease (IBD). METHODS: This international, multicenter, retrospective cohort study consecutively enrolled JAK-inhibitor-treated patients with IBD who subsequently developed acne. The primary objective was to evaluate the clinical characteristics of acne. Secondary objectives included determining acne prevalence, impact on quality of life, and antiacne treatment effectiveness. RESULTS: Among 2183 JAK inhibitor-treated patients with IBD, 272 developed acne. The crude prevalence rates of acne were 15.9% for upadacitinib, 4.3% for tofacitinib, and 1.9% for filgotinib, with dose-dependent relationships observed for upadacitinib and tofacitinib. Acne predominantly affected patients aged 30-50 years; most cases were mild-moderate in severity. A prior history of acne vulgaris was associated with significantly increased odds of developing severe JAK inhibitor-associated acne (odds ratio, 4.88; 95% confidence interval, 2.88-31.7; P = .0003) and acne-related skin complications (odds ratio, 3.92; 95% confidence interval, 1.56-10.11; P = .004). One-third of patients reported a negative psychosocial impact, and 40% received pharmacologic intervention. Eighteen percent of patients who developed acne required JAK inhibitor dose reduction or discontinuation, although most did not have severe disease. CONCLUSIONS: This is the first study characterizing this adverse event in JAK inhibitor-treated patients with IBD and presents the largest cohort of JAK inhibitor-induced acne cases across all immune-mediated diseases. Acne is a common adverse effect resulting in significant psychological burden. Early identification, proactive counseling, and timely interventions, such as dose reduction or referral to dermatology, are crucial in managing this side effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acne VulgarisInflammatory Bowel DiseasesJanus Kinase InhibitorsHumansRetrospective StudiesMaleFemaleAdultMiddle AgedYoung AdultPrevalenceAdolescentAgedPyrimidinesQuality of LifePiperidines

Stichwörter der Autor:innen

AcneAdverse EventFilgotinibJanus Kinase InhibitorsTofacitinibUpadacitinib

Substanzen

Janus Kinase InhibitorstofacitinibPyrimidinesPiperidines

Autor:innen und Institutionen

  • School of Immunology and Microbial Sciences, King's College, London, United Kingdom; Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France. Electronic address: sailish.honap@kcl.ac.uk.
  • Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France; Gastroenterology Department, Unidade Local de Saúde de Coimbra, Portugal.
  • Inflammatory Bowel Disease Unit, Department of Gastroenterology, St Mark's Hospital, London North West University Healthcare NHS Trust, London, United Kingdom.
  • Department of Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, United Kingdom.
  • Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, United Kingdom.
  • IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom.

Zitieren

APA

Honap, S., Temido, M. J., Shakweh, E., Badrulhisham, F., Shields, N., Mehta, S., McBride, J., Uzzan, M., Lukáš, M., Fumery, M., Nogami, A., Kobayashi, T., Nancey, S., Neves, J. C., Mendes, J. M., Wegener, B. A., Bergereau, E., Fernandes, R., Kuzhiyanjal, A. J. K., …, & JAKne International Study Group (2026). Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study. Clinical Gastroenterology and Hepatology, 24(2), 484-492.e7. https://doi.org/10.1016/j.cgh.2025.04.031

Vancouver

Honap S, Temido MJ, Shakweh E, Badrulhisham F, Shields N, Mehta S, et al. Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study. Clinical Gastroenterology and Hepatology. 2026;24(2):484-492.e7. doi:10.1016/j.cgh.2025.04.031

BibTeX
@article{Honap2026,
  author = {Honap, Sailish and Temido, Maria José and Shakweh, Eathar and Badrulhisham, Fakhirah and Shields, Natalie and Mehta, Sonia and McBride, Jodie and Uzzan, Mathieu and Lukáš, Milan and Fumery, Mathurin and Nogami, Akira and Kobayashi, Taku and Nancey, Stephane and Neves, Joana Camões and Mendes, João Martins and Wegener, Birte-Antina and Bergereau, Emilie and Fernandes, Rita and Kuzhiyanjal, Anish John Kuriakose and Vieujean, Sophie and Spencer, Ashley and Baillie, Samantha and Estevinho, Maria Manuela and Simão, Inês and O'Neill, Catarina and Gututui, Madalina and Thompson, Ellen and Jama, Amina and Chai, Ningyu and Pavlidis, Polychronis and D'Amico, Ferdinando and Limdi, Jimmy and Magro, Fernando and Sebastian, Shaji and Digby-Bell, Jonathan and Parkes, Gareth C and Din, Shahida and Hart, Ailsa and Peyrin-Biroulet, Laurent and JAKne International Study Group, JAKne International Study Group},
  title = {Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {2},
  pages = {484--492.e7},
  doi = {10.1016/j.cgh.2025.04.031}
}
Kostenlos starten →